Company Profile
Ulisse BioMed S.p.A. is a biotechnology company specialized in developing medical diagnostics, theranostics and therapeutics solutions. The company has 3 technology platforms, namely, Sagitta (molecular diagnostics), NanoHybrid (theranostics and diagnostics) and Aptavir (therapeutics). Net sales break down by source of revenue as follows:
- royalties (72.2%);
- product sales (27.8%).
Italy accounts for all net sales.
- royalties (72.2%);
- product sales (27.8%).
Italy accounts for all net sales.
Source: Cofisem - Last Update: 2024-02-27
Key Executives
| Chief Executive Officer | |
| Chief Investor Relations Officer |
Source: Cofisem - Last Update: 2024-02-27
Key Figures
| Millenium | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Net sales | 138 | 277 | 429 | 11 | 0 |
| Consumed purchases | 328 | 117 | 141 | 116 | 178 |
| Labour costs | 330 | 141 | 111 | 524 | 610 |
| Operating profit | -1,306 | -604 | 224 | -1,116 | -1,647 |
| Income tax | 0 | 0 | 2 | -18 | 0 |
| Net income | -1,308 | -604 | 222 | -1,098 | -1,933 |
| Net income (Group share) | -1,308 | -604 | 222 | -1,098 | -1,933 |
| Fiscal year end | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards | US GAAP | US GAAP | US GAAP | US GAAP | US GAAP |
Source: Cofisem - Last Update: 2024-02-27
Shareholder information
| Rudy Ippodrino | |
| Bruna Marini | |
| Matteo Petti | |
| Copernico Innovazione S.r.l. | |
| Free float |
Source: Cofisem - Last Update: 2024-02-27
Address
Ulisse BioMed S.p.A.
Aquileia 17
IT-33100 Udine
Italy
Phone number: +39 040 3757540
https://ulissebiomed.com
Source: Cofisem - Last Update: 2024-02-27
Please contact MyQuestion.Italy@euronext.com for Company Profile support.